Humane Genomics · Jan 2026
Technical update on aptazyme-based selective replication, including validation of an RNA ON-switch and prototype virus HGI536.
A platform to make artificial viruses as cancer therapeutics.
Company research
Public company, workplace, funding, and market signals
Overview
New York City biotech developing precision synthetic oncolytic RNA virus therapies for cancer, with a lead focus on pediatric liver cancer.
Primary product
Precision oncolytic virus therapy platform (lead program HGI627)
Founded
2019
Headquarters
180 Varick Street, Floor 6, New York, NY 10014, United States
Team size
1-10
Industry
Biotechnology Research
Sub-industry
Oncolytic virotherapy / synthetic biology
Offices
180 Varick Street, Floor 6, New York, NY 10014, United States
Alexandria LaunchLabs, New York City, United States
BioLabs@NYU Langone (founding location; moved out in 2025)
Business model
biotechnology R&D
therapeutic development
platform-based drug development
Funding
Stage
Seed
Total raised
$5.3M
Latest round
Seed · Feb 2025
People & investors
Leadership
CEO / Co-founder
Co-founder & Chief Science Officer
Co-founder / Advisor
Director, Science (R&D)
Director
Science Team Lead
Work & culture
Mission-driven, fast-paced, merit-based biotech culture centered on cancer research and synthetic biology.
Compensation
Public postings show a Research Associate salary range of $70,000-$85,000 per year; public H-1B salary data shows roughly $107.6k for a Senior Scientist and $112.1k for a Lead Scientist in New York.
Product & market
Pricing
Not publicly disclosed.
Differentiators
- —Selective infection plus selective replication ('2-factor authentication')
- —Synthetic RNA virus platform
- —VSV-based oncolytic approach
- —Aptazyme-controlled replication / RNA ON-switch
- —Rapid digital design-build-test workflow
- —Potential for systemic delivery and cost-effective production
Technology
synthetic biology
synthetic RNA virus platform
oncolytic VSV
DNA synthesis
computer-aided viral design
DNA assembly
cell transfection
aptazyme-based RNA ON-switch
selective infection and replication
Competitors
HelixNano
METiS Therapeutics
CureGenetics
Scale & contact
Latest news
Humane Genomics · Nov 2025
Humane Genomics and Genezen announced process transfer and cGMP manufacturing for lead candidate HGI627 targeting pediatric liver cancer.
Humane Genomics · Jul 2025
Company moved from BioLabs@NYU Langone to Alexandria LaunchLabs in New York City, gaining expanded infrastructure and an onsite vivarium.
Humane Genomics · Apr 2025
Presented preclinical HGI627 data at AACR 2025, including complete response in xenografts, >99.9% tumor reduction, and high tolerability.
Humane Genomics · Feb 2025
Company announced a seed financing led by Union Square Ventures and described its 2-factor synthetic virology platform and pediatric liver cancer focus.
Jobs and careers at Humane Genomics
0 jobs at Humane Genomics
No open positions
Check back later for new openings